Group B Streptococcus (GBS) Diagnosis Market is driven by rapid development of point-of-care tests
Group B Streptococcus (GBS) is a common cause of life-threatening infections in newborns. GBS diagnosis is performed to detect GBS colonization in pregnant women in their third trimester to prevent early-onset GBS disease in newborns. The traditional diagnostic methods involving culturing techniques are time-consuming and need up to 2 days to generate actionable results. Point-of-care tests for rapid GBS screening are now being developed to address this challenge. These tests can generate results within hours to enable prompt treatment decisions.
The group B streptococcus (GBS) diagnosis market is estimated to be valued at USD 1.58 billion in 2024 and is expected to reach USD 2.28 billion by 2031, growing at a compound annual growth rate (CAGR) of 5.4% from 2024 to 2031.
The current geopolitical tensions are impacting the Group B Streptococcus (GBS) Diagnosis Market growth. With rising conflicts and economic uncertainties, international collaborations on R&D are getting affected. This is slowing down the new product innovations and technology advancements in rapid diagnostic tests for GBS.
Get More Insights On- Group B Streptococcus (GBS) Diagnosis Market
Get This Report in Japanese Language: グループB連鎖球菌診断市場
Get This Report in Korean Language: 그룹 B 연쇄상구균 진단 시장
English
Arabic
Français
Español
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian